- RecruitingPHASE3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
This study compares a new medicine, PF-08046054, with a standard lung cancer treatment, Docetaxel. It's for adults with a certain type of lung cancer that has already been treated and has a specific marker called PD-L1.
For: Non-small Cell Carcinoma · Non-Small Cell Lung Cancer Metastatic · Non-Small Cell Lung CarcinomaUnited States · Argentina · Australia - RecruitingPHASE1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study is testing a new drug, PF-08046054/SGN-PDL1V, alone and with an existing medicine called pembrolizumab, for various advanced cancers. Researchers want to see how safe it is and if it has any effect on the cancer. It's a very early stage study.
For: Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of the Head and Neck · Esophageal Squamous Cell CarcinomaUnited States · Belgium · Canada